RT @GlobalHep: We hope you've registered for #GHS2025 in Los Angeles, March 18-21. @globalhep Director John Ward will co-chair! More info h….

A new study reveals the 3-antigen HBV vaccine (PreHevbrio®) generates superior immunity than single-antigen vaccines. Enhanced T-cell responses to PreS antigens are key to its success. Promising for improving HBV vaccination outcomes. #HBV #Vaccines

Agent-based modeling bridges the gap between controlled human infection models and real-world testing for HCV vaccines. Simulations of trials with PWID show robust design but highlight the need for ≥50% vaccine efficacy to ensure success. #HCV #Vaccines.

This study finds B-cell traits, not broad antibodies, are key in HCV reinfection outcomes! This insight could shape targeted vaccine strategies. #HCV #vaccine

WHO's 2030 targets to eliminate HIV & HCV need fast, real-time viral surveillance. This review covers next-gen sequencing (NGS) methods like genome amplification & tiling PCR to track outbreaks & guide targeted interventions. #NGS #PublicHealth #HCV

High levels of hepatitis B core-related antigen (HBcrAg) at the end of treatment predict a higher risk of hepatitis flare after stopping therapy. Monitoring HBcrAg could be key in guiding treatment decisions for chronic hep B. #LiverHealth #HepatitisB

RT @GlobalHep: At CGHE, we're celebrating #WorldHepatitisDay with our partners throughout July! . Visit to explore….

New research reveals the pervasive global discrimination faced by individuals with hepatitis B, highlighting urgent need for policy changes and greater awareness to combat stigma and promote equality. #HepatitisB #PublicHealth #EndDiscrimination.

New Aussie research has demonstrated that CRISPR-Cas13b can be programmed to target #HepB, paving the way for a possible new therapeutic! Read more here 👉

🚨Applications for the ACHV Young Investigator Awards close today! 🚨 . Students and ECRs can be awarded $4000 for travel to an international conference to present work on HCV or HBV 🛫🧪.

There's only one week left to apply for the ACHV Young Investigator Travel Awards! .If you're a PhD student or ECR studying hepatitis, you could be awarded $4000 AUD for travel to an international conference. Details here 👇

Hepatitis infection can result in different complications in the liver depending on which hepatitis virus is involved. New research has demonstrated that hepatitis B and C impair the mitochondria in different ways, explaining why this occurs. More here:.📌

🚨Calling all PhD students and ECRs (<5 years) studying Hepatitis 🚨 . ACHV is offering two awards to support travel to an international conference in 2024. Applications close May 15th - details here 👇

New Aussie research has shown how two splice variants of #HepB have different impacts on the replication of virus in cells. This is the first step in understanding the possible role of these variants in HBV pathogenesis. Read more here: 📌10.1128/jvi.01538-23.

#Hepatitis B, C and D all cause liver disease, but as viruses they have little in common. New research from @thatliverguy has identified a single factor that can be targeted to limit all three viruses, one step on the path to pan-Hepatitis antivirals. 👉

How can new technologies help solve the complex scientific and clinical problems surrounding #HepB? .Two reviews present the possibilities and problems of some exciting new tools: gene editors (DOI: 10.1016/j.cld.2023.05.006) and flexible assays (DOI: 10.1016/j.cld.2023.05.002).

How can we scale up testing and treatment for #HepatitisC? A new study demonstrates how scaling up testing of dried blood spots can be useful, particularly in resource limited settings. More here 👉

New #HepatitisC research! Australian researchers have mapped how Hep C evolves to evade the immune system, and have identified antibodies that are resistant to escape. This could help us design a better HCV vaccine - read more here:. 📌

We would like to acknowledge the passing of Brett Lindenbach, PhD, late last year. Without Brett’s pioneering work in developing cell culture models of Hep C we would not be armed with the powerful drugs that can cure this infection. Our thoughts are with his family and friends.

Congratulations to Dr Melanie Walker @MelanroseWalker who has been recently awarded the ACHV Research Seed Award!! 🥳🥳 . Read more about Mel's research in to the antibody response to HCV here 👇.doi: 10.1038/s41598-019-49454-w.